BAMF
BLTE

BI Asset Management Fondsmaeglerselskab’s Belite Bio BLTE Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,954
Closed -$92K – 445
2022
Q2 		$92K Buy
+2,954
New +$55.4K ﹤0.01% 446

Other funds holding BLTE

AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
PWMG
Prestige Wealth Management Group Flemington, New Jersey $509M AUM 15.69% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's BLTE Position: Q3 2022 in Review

BI Asset Management Fondsmaeglerselskab sold out of Belite Bio (BLTE) in Q3 2022, closing a stake of 2,954 shares — an estimated $92K sold.

BI Asset Management Fondsmaeglerselskab first reported a position in BLTE in Q2 2022 and held it in 1 quarter. The position peaked at $92K in Q2 2022. 8 funds tracked by Wall St. Rank hold BLTE as of Q3 2022.

  • BI Asset Management Fondsmaeglerselskab reported no remaining Belite Bio position as of Q3 2022 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 2,954 Belite Bio shares in Q3 2022, an estimated $92K.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Belite Bio in Q2 2022 and held it in 1 quarter.
  • BI Asset Management Fondsmaeglerselskab's Belite Bio position peaked at $92K in Q2 2022.
  • 8 funds tracked by Wall St. Rank held Belite Bio as of Q3 2022.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q3 2022, filed 7 Nov 2022.